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Clinical Arrhythmias
Monomorphic ventricular arrhythmias (MMVA) are not uncommon 
in athletes,1,2 yet their presence appropriately raises concern among 
practitioners for possible increased risk of sudden cardiac death 
(SCD) during sports activity and competition. While all MMVA detected 
in athletes warrant further evaluation,1 a majority of MMVA in this 
population are likely to be benign. In some instances of so called 
‘idiopathic’ premature ventricular contractions (PVCs)/ventricular 
tachycardia (VT), the arrhythmia may be unrelated to athletic status 
or may be a benign manifestation of the physiological changes that 
may occur in the ‘athlete’s heart’.2 However, this is a matter of debate,3 
and the presence of MMVA may also be a manifestation of structural 
pathology, such as hypertrophic cardiomyopathy (HCM), myocarditis, and 
arrhythmogenic right ventricular cardiomyopathy (ARVC), or electrical 
abnormalities such as long QT syndrome or Brugada syndrome, which 
are associated with increased risks of SCD with exercise. 
The focus of this review is to discuss the management of athletes 
found to have MMVA, including diagnostic workup, advanced treatment 
options and guidance recommendations for this unique population. 
Epidemiology
MMVA can range from PVCs to non-sustained VT (NSVT) and 
sustained VT. MMVA can be seen in trained athletes on 12-lead 
ECG or ambulatory ECG monitoring and in most cases there are no 
cardiovascular abnormalities detected on further workup.4 The overall 
prevalence of MMVA does not appear to be higher in the athlete 
population. A recent study found that the prevalence of MMVA in 
a group of young athletes (16–35 years) in Italy (10%) was similar 
to that of sedentary controls (11%).5 Similar findings were observed 
in an older population of athletes (>30 years), although the overall 
prevalence of MMVA was higher in the older population overall (26% 
in athletes and 23% in sedentary controls).3 Interestingly, in both 
studies, the prevalence of MMVA was not associated with the amount 
and duration of exercise. While there are some data suggesting 
that MMVA are often either abolished or substantially reduced in 
frequency with detraining,6 the similar prevalence between athletes 
and non-athletes suggests that in most patients there is no cause-
effect relationship between athlete status and arrhythmia in persons 
without known structural heart disease.
PVCs are not uncommon in athletes, yet whether there is a higher 
prevalence of PVCs specifically in athletes compared with the general 
population is unclear. One of the early studies comparing PVC 
frequency between endurance athletes and healthy sedentary people 
found a higher prevalence of ventricular ectopy in the athlete group, 
which included both any ectopy (70% versus 55%) and complex 
ectopy (25% versus 5%).7 However, subsequent studies have not seen 
a significant difference in athletes.3,5,8 Younger athletes (mean age 
21 years) were found to be more likely to have isolated, rare ectopy 
(<10 PVCs/24 hours) compared with their sedentary counterparts (49% 
versus 28%),5 but this difference was not seen in a study of middle-
aged athletes and sedentary controls (53% versus 50%).3
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Clinical Arrhythmias
Interestingly, while idiopathic PVCs are often thought to be 
sympathetically mediated, there appears to be variability in the circadian 
distribution of PVC occurrence among patients. In a recent study of 101 
consecutive unselected patients with frequent monomorphic PVCs 
referred for radiofrequency catheter ablation (RFA), 50.5% were found 
to have fast heart rate-dependent PVCs (more PVCs occurred at higher 
heart rates), whereas 9.9% had slow heart rate-dependent PVCs (more 
PVCs at lower heart rates).9 No correlation between heart rate and 
PVC frequency was seen in the rest of the patients (39.6%). However, 
the circadian variability of PVCs in athletes has not been specifically 
studied and further data is needed to determine how different sub-
types of PVCs/VT should be managed in athletes. 
Evaluation 
The initial diagnosis of MMVA in athletes may present in a variety 
of ways, including incidental detection on screening ECGs or after 
workup performed for symptoms such as palpitations. While most 
of these arrhythmias are likely to be benign, it is crucial to identify 
features that may be suggestive of underlying structural heart disease, 
warranting not only further workup but also potentially restriction 
from sports activity or competition. Beyond the routine history 
and physical examination that should be performed in all patients 
presenting with MMVA, important features to assess in athletes include 
arrhythmia frequency, response of the arrhythmia to exercise and 
electrocardiographic patterns (Figure 1).
Clinical Assessment
While some athletes who are referred for evaluation of MMVA may 
be asymptomatic with an incidental finding of irregular heartbeat,3,4,8 
it is imperative to perform a detailed history to identify any 
concerning symptoms that the athlete may not otherwise mention 
unprompted. Specific symptoms to inquire about include palpitations, 
light-headedness, dizziness/presyncope, syncopal episodes, typical 
and atypical chest pain, dyspnoea that is sudden in onset or out 
of proportion to the degree of exercise, sudden fatigue, nausea, 
abdominal pain, or decreased exercise performance. Furthermore, 
family history should be queried for sudden death, syncope, or known 
cardiac disease, and basic laboratory tests – including a chemistry 
panel and thyroid function tests – should be performed to assess for 
possible contributions from electrolyte or endocrine abnormalities.
In addition to the physical exam, non-invasive studies that should 
be performed in athletes with MMVA are a 12-lead ECG, ambulatory 
ECG monitor (i.e. 24-hour Holter or 2–4 week event monitor), exercise 
stress testing and a transthoracic echocardiogram.10 On the 12-lead 
ECG, the most recent version of the international recommendations 
on ECG interpretation in athletes should be used to identify abnormal 
findings,11 which may be suggestive of pathologies (e.g. HCM and 
ARVC) that can predispose an athlete to MMVA.12 Prior ECGs should 
be reviewed when available, and it may also be useful to obtain serial 
ECGs. It is also important to differentiate normal variants associated 
with different racial groups, such as early repolarisation seen in 
athletes of Afro-Caribbean descent where the ECG commonly shows 
elevated ST segments with upward concavity followed by negative 
T wave in V2-V4.13 The exercise stress testing protocol should be 
based on maximal effort, not a target heart rate, and attempts should 
be made to replicate the level and form of exercise achieved in the 
athlete’s sport.1 The findings on these initial studies may prompt 
further evaluation, which may include but are not limited to coronary 
computed tomographic angiography and cardiac MRI.
Arrhythmia Frequency/Burden
The frequency/burden of PVCs/VT can be quantified by ambulatory 
ECG monitoring including 24–48 hour Holter monitoring or 14–30-day 
event recorders. The type of monitor chosen should be determined 
by the frequency with which the athlete experiences symptoms; 
if asymptomatic, a 24–48-hour Holter monitor is a reasonable first 
option. In a study of 355 athletes with ventricular arrhythmias detected 
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Figure 1: Flow Diagram of Proposed Evaluation for Athletes with Monomorphic Ventricular Arrhythmias 
General recommendations for initial evaluation of an athlete who presents with MMVA, with further management depending on the results of exercise stress testing. CTA = computed 
tomographic angiography; EP = electrophysiology; MMVA = monomorphic ventricular arrhythmias; PVC = premature ventricular contractions; VT = ventricular tachycardia.
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on a 24-hour Holter monitor obtained because of palpitations and/
or ≥3 PVCs on a resting ECG, 30% of athletes who had ≥2000 PVCs 
in the 24-hour period were found to have cardiac abnormalities on 
further workup; of those athletes with abnormalities, ARVC (10%) and 
mitral valve prolapse (9%) were most common. Conversely, cardiac 
abnormalities were seen in only 3% and 0% of athletes with ≥100–2000 
PVCs or <100 PVCs, respectively.4 Thus, a higher frequency of PVCs 
(>2000 in a 24-hour period) should raise suspicion for structural heart 
disease and warrants further evaluation. Furthermore, the presence 
of multiple (≥2) PVCs on a resting 12-lead ECG should prompt further 
evaluation, with at least an echocardiogram, an ambulatory ECG 
monitor and exercise stress testing.11
Response of Arrhythmia to Exercise
The response of PVCs to exercise can offer insight into the likelihood 
of underlying cardiac disease.14 Monomorphic PVCs that decrease 
or disappear with exercise are generally considered to be benign.1 
Conversely, a recent study found that athletes who had increased 
ventricular arrhythmia (VA) with exercise were more likely to have 
pathological myocardial substrate on cardiac MRI than those who had 
decreased VA with exercise.15 In older athletes, the primary concern 
of increasing ectopy with exercise is an ischaemic aetiology. In a 
recent meta-analysis of ten studies evaluating exercise-related PVCs 
during clinical stress testing, exercise-related PVCs correlated with 
an increased risk of adverse cardiac events, even in asymptomatic 
patients without overt cardiovascular disease.16 Interestingly, the 
sensitivity analyses found that only PVCs seen during the recovery 
phase of stress testing were associated with adverse outcomes. 
Notably, these studies did not focus on athletes. 
Electrocardiographic Patterns in Risk Stratification
Attempts to localise the origin of the PVC/VT may be helpful for 
risk stratification. PVCs originating from the right ventricular outflow 
tract (RVOT), suggested by a left bundle branch block (LBBB) pattern, 
inferior axis and precordial transition at or after V3 are likely to be 
benign (although this pattern can sometimes be seen in ARVC). The 
precordial transition is the V-lead in which the QRS changes from 
a predominantly negative S wave deflection to a positive R wave 
pattern. PVCs of left ventricular outflow tract (LVOT) origin (i.e. LBBB 
pattern and inferior axis with early precordial transition) and fascicular 
origin (i.e. RBBB pattern and superior axis for posterior fascicular 
sites) are less common, but also generally considered to be benign.17 
On the other hand, morphological features that raise concern for 
pathology include any pattern not typical of a classic idiopathic 
site of origin, markedly widened QRS intervals (>140 ms) and/or a 
pleomorphic pattern of PVCs, as these suggest an atypical site of 
origin or multiple sites of origin. Additionally, the PVC coupling interval 
can be assessed, and a short coupling interval may raise concern 
for an increased risk of an R-on-T phenomenon and polymorphic 
ventricular arrhythmias. When assessing exercise-induced ventricular 
arrhythmias, Cipriani and colleagues demonstrated that repolarisation 
abnormalities at baseline, complex VA (couplets, triplets, NSVT) on 
24-hour ambulatory ECG monitoring, and repetitive exercise-induced 
VA with RBBB or polymorphic morphology have been associated with 
higher risk of structural heart disease on cardiac MRI.15 Slower (<150 
BPM), monomorphic patterns are more likely to be benign compared 
with faster and polymorphic patterns,1 but there are exceptions. For 
instance, benign idiopathic outflow tract VT can often be very fast 
(Figure 2), while pathological scar-mediated VT in ARVC may have a 
slower rate (Figure 3).  
Differential Diagnosis
Age has a strong influence on the differential diagnosis: older athletes 
(>35 years) are more likely to have atherosclerotic coronary artery 
disease (CAD) and ischaemic heart disease as an aetiology, whereas 
younger athletes (<35 years) are more likely to have congenital 
abnormalities, such as anomalous origin of a coronary artery, familial 
cardiomyopathy or a genetic predisposition to arrhythmia.14 
Structural Heart Disease
Familial cardiomyopathies include HCM, ARVC, and left ventricular non-
compaction cardiomyopathy. These conditions need to be considered 
in all athletes with VA, but particularly in younger athletes given that 
HCM and ARVC may manifest as VA at an early age. In a seminal 
study from 1996 by Maron et al. on SCD in young athletes, HCM 
Figure 2: Idiopathic (Outflow) Ventricular Tachycardia 
Figure 3: Monomorphic Ventricular Arrhythmias in 
the Setting of Arrhythmogenic Right Ventricular 
Cardiomyopathy 
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A: RAO fluoroscopic view of outflow tracts after simultaneous pulmonary artery and aortic 
root angiography; B: A similar anatomic view with the RV free wall removed; C: A similar 
view after completion of a 3D electro-anatomic map (Biosense Webster) prior to RFA; D: 
12-lead ECG of a PVC with a left bundle, inferior axis morphology, with precordial transition 
at lead V3, consistent with outflow origin. AIV = anterior interventricular vein; AO = aorta; CC 
= coronary cusp; CS = coronary sinus; HIS, = bundle of HIS; LAD = left anterior descending 
artery; PA = pulmonary artery; RAO = right anterior oblique; RV = right ventricle; RVOT = right 
ventricular outflow tract; TV = tricuspid valve. Image B is reproduced with permission from 
the UCLA Cardiac Arrhythmia Center, Wallace MacAlpine Collection.
 A: Electrocardiographic findings of epsilon waves visualised in lead V1 when the athlete is 
in normal sinus rhythm; B: Atypical LBBB VT originating from the apical aspect of the right 
ventricular free wall; C: RAO angiographic view at the time of EP study/RFA demonstrating 
markedly enlarged RV on angiography (yellow outline); D: Catheter positions during mapping 
and RFA of VT shown in panel B. RFA was undertaken using a combined endocardial and 
epicardial approach. ABL = ablation catheter; ANGIO = angiographic; ARVC = arrhythmogenic 
right ventricular cardiomyopathy; cath = catheter; EPI = epicardial; LBBB = left bundle branch 
block; MMVA = monomorphic ventricular arrhythmias; RA = right atrium; RV = right ventricle; 
VT = ventricular tachycardia.
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was found to be the most common structural cardiovascular cause 
of death, followed by anomalous origin of the coronary arteries.18 A 
more recent 10-year study from Australia similarly found that a familial 
cardiomyopathy (HCM or ARVC) contributed to approximately 33% 
of sport-related SCD in children,19 and an analysis of a UK registry 
found that myocardial disease (including left ventricular hypertrophy 
and fibrosis, HCM and ARVC) accounted for 40% of SCD in athletes.20 
Interestingly, HCM was found to be a more common cause of SCD in 
male athletes, while anomalous origin of the coronary arteries was the 
more common cause in female athletes.21 However, the SCD reported 
in studies of patients with HCM is often related to polymorphic VT/VF, 
although they can also present with MMVA. 
In older athletes with MMVA, atherosclerotic CAD should be considered, 
as it is the most common aetiology of sport-related SCD in this 
group, presumably due to ischaemic scar-related VA.19 Other structural 
pathologies that can lead to MMVA in athletes of any age include 
arrhythmogenic inflammatory cardiomyopathy (including sarcoidosis and 
myocarditis)22,23 and valvular abnormalities (e.g. mitral valve prolapse).24,25
Electrical Heart Disease 
While structural heart disease needs to be evaluated in athletes 
with MMVA, the most common finding in athletes who experienced 
SCD is a structurally normal heart,26 and the most common cause of 
SCD in children and adolescent athletes is sudden arrhythmic death 
syndrome (SADS).20 Presumably, SADS is because of undiagnosed 
inherited arrhythmia disorders, such as ion channelopathies.27 These 
channelopathies include long QT syndrome, Brugada syndrome and 
catecholaminergic polymorphic ventricular tachycardia, but more 
commonly manifest as polymorphic VA and are thus outside of the 
scope of this review on MMVA. 
Management
The management of any athlete with known or possible cardiovascular 
disease, especially MMVA, can be particularly challenging because 
of the large role that physical activity and competitive sports plays in 
the athlete’s personal and/or professional life. Management decisions 
therefore require a shared-decision making approach that emphasises 
the need to prioritise the athlete’s safety, including providing a 
temporary or indefinite recommendation to refrain from strenuous 
exercise or competition. However, it should be noted that certain 
sporting organisations may require medical ‘clearance’ for competitive 
participation and the athlete may have less autonomy in these situations. 
Restriction from Competitive Sports 
Before an athlete with known or suspected MMVA can be cleared 
to return to competitive sport participation, a cardiac evaluation 
– comprising at least of an exercise stress test targeting maximal 
performance, echocardiogram and ambulatory ECG monitoring – is 
recommended.1,10 Based on the American Heart Association (AHA) 
and American College of Cardiology (ACC) recommendations, absent 
of any structural or electrical heart disease or high-risk ECG features, 
athletes who demonstrate no greater than PVC couplets during 
maximal exercise testing, ideally recapitulating their sport of choice, 
can participate in all competitive sports.1 The European Society of 
Cardiology (ESC) recommendations also include stipulations that 
there be no family history of SCD, no increased PVC frequency during 
exercise, and overall PVC burden <2000 per 24 hour for clearance 
to participate in all sports.28 If exercise testing results in increased 
VA frequency, repetitive forms of PVCs, NSVT or sustained VT, then 
the athlete should be given the recommendation to refrain from 
participation in competitive sports until further evaluation and/or 
treatment are performed.1,28 
Athletes found to have structural heart disease or evidence of 
myocarditis should be advised to restrict themselves to playing low 
intensity (Class IA) sports, such as bowling and golf (Figure 4). In 
particular, while expert opinion suggests that those with myocarditis 
may potentially be able to return to higher-intensity sports after 
evaluation for complete resolution of their condition,1,28 athletes with a 
diagnosis of ARVC should be counselled extensively on the importance 
of refraining from strenuous exercise indefinitely, as exercise in these 
patients is associated with a high risk of a lethal VT.29–31 High-intensity 
exercise, independent of exercise duration, increases risk in patients 
with ARVC,32 and exercise restriction has indeed been found to 
reduce VT frequency.33 Athletes without overt ARVC, but who have a 
desmosomal mutation associated with ARVC, are at increased risk of 
developing ARVC, heart failure, and/or lethal VT with endurance and/
or frequent exercise.34 These athletes should also be counselled to 
refrain from endurance exercise and high-intensity sports (above Class 
IA), but can likely still safely adhere to the AHA’s minimal exercise 
recommendations (450 to 750 metabolic equivalent-minutes weekly).35 
Interestingly, it has been reported that high-intensity endurance 
exercise itself may result in ARVC-like pathology, including an increased 
risk of VT, without any detected genetic mutation (‘gene-elusive’).36–38 
In addition, a recent study found a distinct pattern of isolated 
subepicardial RVOT scar associated with MMVA in high-level endurance 
athletes that is amenable to RFA.39 However, little is known about the 
potential need for post-ablation exercise limitations in this patient 
population. Further, a small study of seven asymptomatic athletes with 
extensive subepicardial late gadolinium enhancement on cardiac MRI 
found that six of the seven developed symptomatic VT or progressive 
LV dysfunction.40 The aetiology of the subepicardial scar was unknown 
in these athletes, and this study supports comprehensive evaluation 
and close follow-up in those athletes found to have myocardial fibrosis 
on cardiac MRI. 
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Figure 4: Classification of Sports by Static and Dynamic 
Components 
General guidelines classifying sports based on the peak static and dynamic components 
typically reached during competition (although higher values can be achieved). *Sport 
presents danger of bodily collision. †Sport carries increased risk if syncope occurs.
Source: Levine et al., 2015.59 Reproduced with permission of Levine et al. and the Journal of 
the American College of Cardiology. 
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Prescribed Deconditioning
In athletes without structural or electrical heart disease, prescribed 
periods of deconditioning (ranging from 12–24 weeks) have been 
shown to reduce the frequency of MMVA.6 The beneficial effects of 
periods of deconditioning on frequency reduction appear to persist 
after a resumption of intensive training, when compared with the 
MMVA frequency prior to deconditioning.41 However, in practice, 
athletes are often reluctant to participate in deconditioning periods. 
Reassuringly, one study assessed 120 athletes with no obvious 
structural heart disease found to have a modest burden of PVCs 
(>100/24 hours) on routine pre-participation screening.42 Continued 
sports activity in these athletes did not result in any deaths or 
development of overt heart disease, and overall modest PVC burden 
actually decreased over the median follow-up period of 84 months. 
Thus, as long as there is no evidence of overt structural or electrical 
heart disease, deconditioning is an optional recommendation for 
many athletes with MMVA. 
Medical Management
In symptomatic athletes, medical therapy can be considered 
to reduce symptoms and MMVA frequency. For athletes with 
symptomatic PVCs or a high PVC burden, beta-blocker therapy can 
be effective at reducing PVC frequency, and the ESC recommends 
beta-blockers as first-line medical therapy for the treatment of 
MMVA.43 Additionally, beta-blockers can be considered for athletes 
with NSVT induced by exercise, and documentation of resolution of 
NSVT with exercise on beta-blocker therapy is required before an 
athlete can be cleared to return to competitive sport participation.1 
However, it should be noted that beta-blockers may have limited 
utility/tolerance in athletes given the high baseline parasympathetic 
tone (and associated resting bradycardia) seen in elite athletes, as 
well as the possible adverse effects these medications may have on 
athletic performance. Further, some sporting organisations actually 
prohibit the use of beta-blockers in athletes during competition, and 
physicians should review and remind their athlete patients to review 
the list of prohibited classes of medications prior to prescribing any 
new medication. Of note, there is no evidence at this time to support 
the use of antiarrhythmic medications to suppress benign PVCs in 
athletes.14 For patients with PVC-induced cardiomyopathy, however, 
there are recent data to suggest the safety and efficacy of class 
IC antiarrhythmic medications, such as flecainide in an unselected 
patient population.44
For athletes with idiopathic MMVT, medical therapy can be considered 
if RFA is not possible or not desired,45,46 and the location of VT origin can 
be influential in guiding therapy. For instance, fascicular VT has been 
found to be responsive to the non-dihidropyridine calcium channel 
blocker verapamil, as well as beta-blockers. For outflow tract VT, class 
IC and class III antiarrhythmic medications are more effective than 
beta-blockers or calcium channel blockers, and can be considered as 
long as there is no evidence of structural heart disease.46 However, the 
side effect profiles of antiarrhythmic medications need to be strongly 
considered prior to initiation in any athlete and beta-blockers are 
usually the first choice given the safety profile. 
Radiofrequency Catheter Ablation
Many athletes, particularly younger ones, are reluctant to take 
medications because of concerns about their side effects and 
their possible impact on athletic performance. Fortunately, RFA of 
MMVT – previously limited to experienced academic centres – is 
now being increasingly performed internationally as more cardiac 
electrophysiologists gain advanced training in the procedure.47 
For athletes with symptomatic PVCs, RF ablation of PVCs may be 
considered if the PVCs are refractory to medications or if the athlete 
is unable or unwilling to take medications.1 In contrast to medications, 
RFA can be curative of MMVAs. In fact, for PVCs with an RVOT origin, 
RFA was found to be more effective than antiarrhythmic drug therapy 
in preventing recurrence,48 and a multi-centre study found RFA to have 
an 84% acute success rate with a low complication rate (2.4% major 
complications and 2.8% minor complications).49 Complications were 
most commonly related to vascular access, but rare complications 
including cardiac tamponade and atrioventricular block can occur. 
Notably no procedure-related stroke or deaths were seen in the 1,185 
patients included in the study.49 
Furthermore, given the association of PVC frequency with an increased 
risk of heart failure (PVC-induced cardiomyopathy),50 it is reasonable to 
consider RFA in athletes with a high PVC burden and/or a reduction 
in systolic function due to PVCs.43 RFA of PVCs originating from the 
LVOT, aortic cusp, or epicardial origin should only be undertaken 
at experienced centres. For athletes with idiopathic, monomorphic 
sustained VT, RFA is also a reasonable therapeutic option.1
In patients with MMVT associated with structural heart disease, such as 
ARVC and HCM, RFA can be considered, particularly if they are highly 
symptomatic or are experiencing frequent ICD therapies. A recent 
retrospective study of VT ablation in patients with non-ischaemic 
cardiomyopathy found that the outcomes of VT ablation differed 
based on the underlying etiology.51 Patients with ARVC had the highest 
VT-free survival 1 year after RFA (82%), while patients with HCM had a 
relatively higher rate of VT recurrence after ablation. In another recent 
study focused on patients with ARVC VT, RF ablation was associated 
with similar outcomes compared to drug therapy, although combined 
epicardial-endocardial RF ablation resulted in lower VT recurrence 
compared with an endocardial alone approach.52 Similarly, in a small, 
highly selected group of patients with MMVT associated with HCM, 
combined epicardial-endocardial RFA was effective at preventing 
recurrence of ICD shocks in 78% of patients at a median follow-up of 
37 months.53 Thus, RFA can be an effective option for select patients 
with ARVC and HCM. However, given the presence of structural heart 
disease, RFA therapy does not allow for return to athletic competition, 
even if successful, as the procedure may eliminate the clinical 
arrhythmia but does not resolve the underlying pathology and future 
development of new VT circuits is possible. 
Device Implantation
The decision to implant an ICD in athletes is a particularly challenging 
one, as it may impact their ability to continue competition in their 
chosen sports.54 Additionally, potential complications of ICDs include 
inappropriate shocks, device-related infections and lead failure. In 
particular, with transvenous ICD systems, repetitive arm motion 
during athletic activity may result in lead dislodgement with resulting 
sensing failure or in lead fracture and inappropriate shocks.55 The 
recently available subcutaneous ICD may have a lower risk of 
lead malfunction.56 The recommendations for ICD implantation in 
athletes follow the same guideline recommendations for primary 
and secondary prevention in the general population. The AHA/ACC 
guidelines state that athletes who have survived a cardiac arrest 
due to MMVA should have an ICD placed.1 Additionally, athletes who 
have had documented symptomatic rapid monomorphic VT from a 
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non-reversible cause should also have an ICD placed if not idiopathic 
in origin.1 In a multinational registry of 440 athletes with implanted 
transvenous ICDs and median follow-up of 44 months, the proportion 
receiving appropriate shocks during competition/practice was 11%; 
ARVC was the only clinical factor associated with receiving a shock. 
The estimated lead survival free of malfunction was 95% at 5 years 
and 85% at 10 years; there were no generator malfunctions.57 Notably, 
the AHA/ACC guidelines reiterate that the desire of an athlete to 
continue participation in athletic competition does not qualify as an 
indication for ICD implantation, and it is inappropriate to implant an 
ICD solely to allow for return to athletic competition.1 
Return to Competitive Sports and Physical Activity
After comprehensive evaluation of an athlete with MMVA, the 
recommendations on continued participation in competitive sports 
hinges on the presence of structural and/or electrical heart disease 
as well as response to therapy. In athletes without structural heart 
disease who have single PVCs and no greater than ventricular 
couplets during maximal exercise testing, participation can be 
allowed in all competitive sports without further evaluation.1 If PVCs 
either increase in frequency or cause symptoms during exercise 
(such as light-headedness, excessive fatigue, or excessive dyspnoea), 
the athlete should be restricted to sports below the exertional level at 
which these occurred until further evaluation (e.g. echocardiography, 
cardiac MRI, electrophysiological testing) has been performed and 
structural heart disease ruled out and treatment initiated. If the 
athlete has been started on drug therapy such as beta-blockers, 
return to participation should only occur if there is documentation 
on either exercise or electrophysiological testing that the MMVA 
no longer occurs under the physiological conditions in which it 
previously occurred prior to medical therapy. In athletes who have 
had successful RFA of their MMVA, return to full competitive activities 
can be allowed if there is no evidence of spontaneous or induced VA 
at least 3 months after the date of their procedure in the setting of a 
structurally normal heart.1
Athletes with structural heart disease with documented NSVT 
should be restricted to low-intensity class IA sports (Figure 4), even 
if they have undergone successful RFA of the MMVA.1 Notably, 
the data supporting this recommendation are limited (Class 
IC recommendation from the AHA/ACC). As mentioned above, 
continued high-intensity physical activity can promote progression of 
conditions such as ARVC, and athletes with these diagnoses should 
be counselled extensively on these risks. However, in athletes whose 
MMVA are a result of a transient inflammatory process such as 
myocarditis, re-evaluation for return to competition is recommended 
after there is clinical and laboratory evidence of resolution of the 
inflammation; if there is reasonable evidence to suggest that the 
pathology has fully resolved, the athlete may return to competition 
a minimum of 3 months after clinical resolution.1 However, in 
inflammatory conditions such as cardiac sarcoidosis, there can be 
recurrence of the inflammatory process after dormant periods and 
complete resolution may not occur.  
For athletes who have had an ICD, participation in class IA sports is 
permitted if there is no evidence of MMVA requiring device therapy 
for at least 3 months. Participation in higher-intensity sports may be 
considered after extensive discussion with the athlete on the risks 
involved, including ICD pocket-site injury in impact sports.1 These 
decisions will be diagnosis-dependent, as athletes with diagnoses that 
are known to be negatively impacted by exercise, such as ARVC, should 
be advised against participation in higher-intensity sports. The ICD 
Sports Safety Registry of athletes with ICDs implanted who continue to 
participate in competitive sports, including high-risk sports, has helped 
to inform sports cardiologists and patients on the outcomes of these 
athletes.57,58 In longer-term follow-up of the 440 participants in the 
registry, while there were appropriate and inappropriate ICD shocks in 
some of the athletes, there were no failures to terminate arrhythmias 
and no physical injuries due to the ICD. Freedom from lead malfunction 
(definite or possible) was 85% at 10 years.57 
Conclusion
Athletes with MMVA warrant comprehensive evaluation by a sports 
cardiology program, with experience and expertise as needed in 
paediatric cardiology, adult congenital cardiology, advanced cardiac 
imaging, interventional cardiology, electrophysiology and advanced 
exercise testing. While most of these MMVA will be of a benign nature, 
it is crucial to evaluate for the presence of structural and/or electrical 
heart disease, as continued competitive sport participation may expose 
the athlete to an increased risk of SCD in conditions such as ARVC and 
HCM. In the absence of structural heart disease, the improved outcomes 
of therapeutic procedures such as RFA and improved understanding of 
the management of MMVA in athletes have allowed many athletes to be 
guided safely back towards competition with the guidance of a sports 
cardiologist. In all cases, shared decision making should be central to 
formulating the treatment plan for each athlete. 
Clinical Perspective
• MMVA, including premature ventricular complexes as well as 
non-sustained and sustained VT, are not uncommon in athletes 
and always raise concern about whether an athlete can 
continue to participate in competitive sports.
• Initial assessment includes a comprehensive history and 
physical examination and review of all available ECGs.
• Identifying high-risk features, particularly response to maximal 
exercise testing and presence of structural heart disease, is 
critical to determine safety of continued competitive sport 
participation.
• Echocardiography and frequently cardiac MRI are required to 
evaluate for structural heart disease, as certain conditions (i.e. 
ARVC, HCM) pose an elevated risk of sudden cardiac death 
during competition.
• Treatment options include observation and monitoring, 
exercise restriction, medical therapy, and interventions such as 
RFA and ICD implantation.
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